Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Conditions: Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis Interventions: Drug: SHR6508 Sponsors: Shanghai Hengrui Pharmaceutical Co., Ltd. Not yet recruiting

Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials